Apollomics (APLM)

Its lead programs include vebreltinib, also known as APL-101, a selective c-Met inhibitor being studied for non-small cell lung cancer and other tumors with MET alterations. Abnormal MET signaling can play a role in tumor growth, progression, and resistance to other therapies, making it an important target in precision oncology. Apollomics is also developing uproleselan, or APL-106, an E-selectin antagonist with potential use in combination with chemotherapy for acute myeloid leukemia.

The company’s pipeline further includes immuno-oncology candidates such as APL-501, APL-502, and APL-801, which involve antibody-based approaches, including mono-specific and bi-specific formats. These programs reflect a broader effort to develop treatments that can be paired with other cancer therapies or directed toward defined patient populations.

As a clinical-stage company, Apollomics does not have the profile of a mature pharmaceutical business with diversified commercial revenue. Its value is closely linked to clinical trial progress, regulatory outcomes, partnership opportunities, financing needs, and the competitive landscape in oncology drug development. The company operates in a field where scientific differentiation, patient selection, safety, and durable efficacy are central to long-term success.